Contineum Therapeutics (CTNM) Projected to Post Quarterly Earnings on Thursday

Key Points

• Contineum Therapeutics is expected to report Q3 2026 results before the market opens on October 29. Analysts forecast a loss of $0.45 per share and revenue of $5.65 million; the earnings call is scheduled for October 30 at 4:00 p.m. ET.
• The company previously reported a quarterly loss of $0.40 per share, beating consensus expectations by $0.05. Analysts project full-year and next-year losses of $1.68 and $1.64 per share, respectively.
• Shares opened at $8.35, well below their 50-day and 200-day moving averages of roughly $13.60. Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $22.33.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) is projected to post its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Contineum Therapeutics to announce earnings of ($0.45) per share and revenue of $5.65 million for the quarter. Investors are encouraged to explore the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, October 30, 2026 at 4:00 PM ET.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.05. On average, analysts expect Contineum Therapeutics to post ($1.68) EPS for the current fiscal year and ($1.64) EPS for the next fiscal year.

Contineum Therapeutics Price Performance

Shares of NASDAQ CTNM opened at $8.35 on Thursday. The company's fifty day simple moving average is $13.61 and its 200 day simple moving average is $13.65. Contineum Therapeutics has a 12-month low of $6.72 and a 12-month high of $17.78.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Morgan Stanley decreased their price target on shares of Contineum Therapeutics from $18.00 to $17.00 and set an "equal weight" rating for the company in a research note on Monday, September 28th. Stifel Nicolaus set a $28.00 target price on shares of Contineum Therapeutics in a research report on Wednesday, September 30th. Wall Street Zen lowered shares of Contineum Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, September 19th. Royal Bank Of Canada raised their price target on shares of Contineum Therapeutics from $22.00 to $23.00 and gave the company an "outperform" rating in a research report on Friday, July 31st. Finally, JonesTrading raised their price target on shares of Contineum Therapeutics from $24.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday, October 15th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $22.33.

About Contineum Therapeutics

Contineum Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines for diseases of the central nervous system. The company's research is centered on therapeutics designed to promote remyelination, the repair of damaged myelin that supports nerve function, and to address neuroinflammation and other mechanisms involved in neurological disorders.

Contineum's pipeline includes PIPE-307, an oral, selective M1 muscarinic receptor antagonist being investigated for its potential to promote remyelination in multiple sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.